Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Sells $91,003.65 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 11,447 shares of the stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $7.95, for a total transaction of $91,003.65. Following the completion of the sale, the director now directly owns 7,218,414 shares of the company’s stock, valued at $57,386,391.30. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, April 16th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.66, for a total transaction of $87,684.02.
• On Tuesday, April 2nd, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $8.82, for a total value of $100,962.54.
• On Tuesday, March 19th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $10.79, for a total value of $216,382.66.
• On Tuesday, March 5th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $12.06, for a total value of $241,851.24.
• On Tuesday, February 20th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $12.32, for a total transaction of $247,065.28.
• On Tuesday, February 6th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $9.30, for a total transaction of $106,457.10.

Recursion Pharmaceuticals Stock Up 0.6 %

Shares of Recursion Pharmaceuticals stock opened at $8.84 on Friday. Recursion Pharmaceuticals, Inc. has a 1-year low of $4.80 and a 1-year high of $16.75. The firm’s 50-day moving average price is $9.88 and its two-hundred day moving average price is $9.18.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Tuesday, February 27th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.06. Recursion Pharmaceuticals had a negative return on equity of 72.88% and a negative net margin of 735.99%. The company had revenue of $10.89 million for the quarter, compared to analysts’ expectations of $12.37 million. Research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.63 earnings per share for the current fiscal year.

Institutional Trading of Recursion Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. National Bank of Canada FI boosted its position in Recursion Pharmaceuticals by 90.9% in the 4th quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock valued at $31,000 after buying an additional 1,500 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its position in Recursion Pharmaceuticals by 6.2% during the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 33,002 shares of the company’s stock valued at $252,000 after purchasing an additional 1,938 shares during the period. Wedmont Private Capital boosted its stake in shares of Recursion Pharmaceuticals by 11.8% in the 1st quarter. Wedmont Private Capital now owns 18,943 shares of the company’s stock valued at $172,000 after purchasing an additional 2,000 shares during the last quarter. Allspring Global Investments Holdings LLC raised its stake in shares of Recursion Pharmaceuticals by 25.4% during the third quarter. Allspring Global Investments Holdings LLC now owns 10,123 shares of the company’s stock worth $77,000 after buying an additional 2,050 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. acquired a new position in Recursion Pharmaceuticals in the first quarter valued at approximately $26,000. 89.06% of the stock is owned by institutional investors.

Analyst Ratings Changes

RXRX has been the topic of a number of analyst reports. TD Cowen began coverage on shares of Recursion Pharmaceuticals in a research note on Friday, January 26th. They issued a “market perform” rating on the stock. Needham & Company LLC reissued a “buy” rating and issued a $17.00 target price on shares of Recursion Pharmaceuticals in a report on Tuesday, April 9th. Finally, KeyCorp boosted their price target on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Monday, March 4th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $12.75.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.